Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 10:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 54,906 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Patient Clear all
Terminated Phase 1 Interventional

Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers

NCT02734615
View directory record Official record
Conditions
Advanced or Metastatic ER+ Breast Cancer
Interventions
LSZ102, LEE011, BYL719
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Oct 31, 2026, 10:11 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

REACH Implicit Bias Training Project

NCT03415308
View directory record Official record
Conditions
Communication, Bias, Racial, Relation, Doctor Patient
Interventions
Focus Groups, Cognitive Interviews, Pilot Testing of Implicit Bias Training
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 31, 2026, 10:11 AM EDT
Completed Phase 3 Interventional

Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes

NCT00044408
View directory record Official record
Conditions
Diabetic Neuropathies, Diabetes Mellitus, Insulin-Dependent, Diabetes Mellitus, Non-Insulin-Dependent
Interventions
Ruboxistaurin mesylate
Drug
Lead sponsor
Chromaderm, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
13
States / cities
Long Beach, California • Norwalk, Connecticut • Clearwater, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2016 · Synced Oct 31, 2026, 10:11 AM EDT
Completed Not applicable Interventional

Pilot: Feasibility of Intermittent Enteral Feeding in Ventilated MICU Patients

NCT04164108
View directory record Official record
Conditions
Nutrition
Interventions
Intermittent Enteral Nutrition Protocol
Dietary Supplement
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Oct 31, 2026, 10:11 AM EDT
Completed Not applicable Interventional

Adaptive Intervention for Adolescents Following Inpatient Psychiatric Care

NCT05282225
View directory record Official record
Conditions
Suicide, Suicide, Attempted, Suicidal Ideation, Self Harm
Interventions
MI- Safety Plan, Texts messages, Monitoring, Portal follow-up, Booster call
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
13 Years to 17 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
3
States / cities
Ann Arbor, Michigan • Detroit, Michigan • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 31, 2026, 10:11 AM EDT
Terminated Not applicable Interventional Results available

Dual Site Left Ventricular (LV) Pacing

NCT00944125
View directory record Official record
Conditions
Congestive Heart Failure, LV Dysfunction
Interventions
Dual Site LV Pacing, BiV Pacing
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Lake Geneva, Wisconsin • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Oct 31, 2026, 10:11 AM EDT
Completed Not applicable Interventional Results available

Individualized Patient Decision Making for Treatment Choices Among Minorities With Lupus

NCT02319525
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Computerized patient decision-aid, Usual care (lupus pamphlet)
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older · Female only
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced Oct 31, 2026, 10:11 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer

NCT03456076
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Alectnib, Cisplatin, Vinorelbine, Gemcitabine, Pemetrexed, Carboplatin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2031
U.S. locations
3
States / cities
Chicago, Illinois • Boston, Massachusetts • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 31, 2026, 10:11 AM EDT
Completed Phase 3 Interventional Results available

A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD

NCT05357989
View directory record Official record
Conditions
Parkinson's Disease, Idiopathic
Interventions
buntanetap/posiphen, Placebo
Drug
Lead sponsor
Annovis Bio Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
523 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
43
States / cities
Birmingham, Alabama • Sun City, Arizona • Fountain Valley, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Oct 31, 2026, 10:11 AM EDT
Active, not recruiting Not applicable Interventional

Wellness App for Sleep Disturbance in Hematological Cancer Patients

NCT05294991
View directory record Official record
Conditions
Cancer, Sleep Disturbance, Anxiety, Depression, Inflammation, Fatigue
Interventions
Wellness app intervention #1, Wellness app intervention #2
Behavioral
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Phoenix, Arizona • Winston-Salem, North Carolina • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 31, 2026, 10:11 AM EDT
Completed Not applicable Interventional

TBTC Study 24: Intermittent Treatment of TB With Isoniazid Resistance or Intolerance

NCT00023374
View directory record Official record
Conditions
Tuberculosis
Interventions
Rifampin, Pyrazinamide, Ethambutol, REZ
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
20
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2011 · Synced Oct 31, 2026, 10:11 AM EDT
Completed Not applicable Interventional

Food Is Medicine for Patients With Heart Failure

NCT06540118
View directory record Official record
Conditions
Heart Failure, Heart Failure，Congestive, Heart Diseases
Interventions
15 Medically Tailored Meals (MTM) per week, 14 Medically Tailored Meals (MTM) per week
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
La Jolla, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 31, 2026, 10:11 AM EDT
Completed Phase 2 Interventional Results available

Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma

NCT02654990
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Panobinostat Capsules, Bortezomib Injection, Dexamethasone tablets
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
9
States / cities
Fayetteville, Arkansas • Los Angeles, California • Fort Collins, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Oct 31, 2026, 10:11 AM EDT
Terminated Phase 1 Interventional

A Phase 1 Dose Escalation Study of AMG 780 in Adult Subjects With Advanced Solid Tumors

NCT01137552
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
AMG 780
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Los Angeles, California • Durham, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 4, 2015 · Synced Oct 31, 2026, 10:11 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer

NCT03246347
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma
Interventions
ADT+Docetaxel+Enzalutamide
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 31, 2026, 10:11 AM EDT
Completed Phase 1 Interventional

Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer

NCT01623349
View directory record Official record
Conditions
Ovarian Cancer, Breast Cancer
Interventions
BKM120 and Olaparib, BYL719 and Olaparib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
5
States / cities
Boston, Massachusetts • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Oct 31, 2026, 10:11 AM EDT
Completed Phase 1Phase 2 Interventional Results available

CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor

NCT04145349
View directory record Official record
Conditions
Desmoplastic Small Round Cell Tumor
Interventions
Ramucirumab, Cyclophosphamide, Vinorelbine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Months to 29 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
6
States / cities
Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 31, 2026, 10:11 AM EDT
Completed Not applicable Interventional

Implementation of Uterine Fibroid Option Grid Patient Decision Aids Across Five Organizational Settings

NCT03985449
View directory record Official record
Conditions
Uterine Fibroid
Interventions
Uterine Fibroid Option Grid encounter patient decision aid (text only), Uterine Fibroid Option Grid encounter patient decision aid (text + Pictures), Uterine Fibroid Option Grid encounter patient decision aid (online)
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
748 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Oct 31, 2026, 10:11 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls.

NCT05084638
View directory record Official record
Conditions
Relapse Remitting Multiple Sclerosis
Interventions
Ofatumumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 35 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
35
States / cities
Chandler, Arizona • Phoenix, Arizona • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 31, 2026, 10:11 AM EDT
Completed Phase 1 Interventional

Acetabular Shell Positioning Using Patient Specific Instruments

NCT01791738
View directory record Official record
Conditions
Osteoarthritis, Hip, Rheumatoid Arthritis, Avascular Necrosis
Interventions
Acetabular positioning system
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 10, 2015 · Synced Oct 31, 2026, 10:11 AM EDT
Recruiting Phase 2 Interventional

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease

NCT06607458
View directory record Official record
Conditions
Refractory Metastatic Colorectal Cancer
Interventions
Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab, Trifluridine-tipiracil plus Bevacizumab Alone
Drug
Lead sponsor
Delcath Systems Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
9
States / cities
Duarte, California • Santa Monica, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 31, 2026, 10:11 AM EDT
Completed Phase 2 Interventional Results available

Erlotinib Hydrochloride With or Without Celecoxib in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer

NCT00499655
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
erlotinib hydrochloride, celecoxib, placebo, laboratory biomarker analysis, immunohistochemistry staining method, fluorescence in situ hybridization, mutation analysis, protein expression analysis, gene expression analysis
Drug · Other · Genetic
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
2
States / cities
Duarte, California • South Pasadena, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 31, 2026, 10:11 AM EDT
Completed Not applicable Interventional

Xavier Electromyographic Wheelchair Control for Limited Mobility Patients

NCT04800926
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Xavier wheelchair controller
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 89 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Oct 31, 2026, 10:11 AM EDT
Completed No phase listed Observational

A Retrospective Analysis of Laboratory Testing on Chronic Wound Patients

NCT02142426
View directory record Official record
Conditions
Wound Chronic Draining
Interventions
Not listed
Lead sponsor
Southwest Regional Wound Care Center
Other
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Nov 26, 2015 · Synced Oct 31, 2026, 10:11 AM EDT